Notably, the observed reductions in the odds of substance use disorders, including a 74% decrease in the odds of AUD, a 69% reduction for OUD, a 68% reduction for NUD, and a 75% reduction for CUD, among GLP-1 RA users were consistent with emerging preclinical and clinical studies showing that GLP-1 RA modulates reward pathways in the brain to reduce SUD (17, 23)
PlexusDx compounded semaglutide injection is $189/mo month-to-month (or $149/mo on the 6-month plan)a flat rate whether you're titrating upward or maintaining your dose
Consult your healthcare professional before use if pregnant, nursing, taking medications, or for any use by minors
Lixisenatide: A new daily GLP-1 agonist for type 2 diabetes management
Surgery: are you a candidate for weight loss surgery